SEHK:3692
SEHK:3692Pharmaceuticals

Does Regulatory Progress for RET Inhibitor Reshape the Oncology Pipeline Momentum at Hansoh (SEHK:3692)?

The board of directors of Hansoh Pharmaceutical Group announced that China's National Medical Products Administration has accepted the New Drug Application for HS-10365 capsules, a selective RET inhibitor for treating adult patients with RET fusion-positive locally advanced or metastatic non-small cell lung cancer. This regulatory milestone not only reflects progress in Hansoh’s oncology pipeline, but also highlights the company’s potential to address significant unmet needs in lung cancer...
SEHK:1286
SEHK:1286Machinery

A Look at Impro Precision Industries (SEHK:1286) Valuation Following Strong Q3 Revenue Growth and Momentum

Impro Precision Industries (SEHK:1286) just posted a strong year-on-year jump in third quarter revenue, with standout gains in its diversified industrials and AI-related segments. The company’s positive sales outlook continues to draw attention from investors. See our latest analysis for Impro Precision Industries. Momentum has clearly shifted in Impro Precision Industries’ favor, with the share price climbing 12.87% over the past month and surging 65% in the last quarter. That is part of a...
SEHK:9973
SEHK:9973Auto

Chery Automobile (SEHK:9973): Evaluating Valuation as Shares Trade in a Tight Range

Chery Automobile (SEHK:9973) has been trading in a relatively narrow range, with its share price closing at HK$32.38. Over the past month, the stock edged up by 1%, reflecting investors’ cautious optimism. See our latest analysis for Chery Automobile. Momentum has been fairly muted for Chery Automobile, as this year’s modest 1.4% share price return suggests investors are still waiting to see if recent progress translates into stronger growth. After a flurry of updates earlier in the year, the...
SEHK:2331
SEHK:2331Luxury

Li Ning (SEHK:2331): Assessing Valuation After Q3 2025 Earnings Call Spurs Investor Focus

Li Ning (SEHK:2331) just held its Q3 2025 earnings call, drawing focused attention from investors and analysts. These quarterly updates provide a revealing look at the company’s financial health and management’s outlook for the months ahead. See our latest analysis for Li Ning. Li Ning’s Q3 earnings call appears to have been a catalyst for movement, with the share price rising 1.75% on the day but pulling back 7.05% over the past week. While short-term volatility remains, the company’s total...
SEHK:579
SEHK:579Renewable Energy

Beijing Jingneng Clean Energy (SEHK:579): Expanding Margins Reinforce Investor Optimism Despite Slower Growth

Beijing Jingneng Clean Energy (SEHK:579) posted stable earnings, with average earnings growth of 6.5% per year over the past five years and net profit margins improving from 14.4% to 14.9%. Earnings growth for the most recent year came in at 5.8%, slightly below the company’s longer-term pace. Future earnings are forecast to increase 8.43% per year and revenue is expected to grow at 3.7% per year. Investors will likely focus on the company’s steady profit and revenue performance, as well as...
SEHK:1798
SEHK:1798Renewable Energy

Datang Renewable (SEHK:1798) Margin Compression Tempers Bullish Growth Narrative Despite 19% Earnings Forecast

China Datang Corporation Renewable Power (SEHK:1798) is guiding for earnings growth of about 19% annually, easily outpacing both the Hong Kong market’s 12% average and the expected 8.6% for market revenue. The company’s current net profit margin sits at 13.2%, a compression from last year’s 14.9%, while average annual earnings growth over the past five years has been 7.9%. With these numbers illustrating robust forward expectations but pointing to mixed margin dynamics, investors are...